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The mechanisms responsible for this range of abnormal angiogenesis in different tissues in patients with diabetes are poorly understood, but relate at least in part to differential expression of hypoxia-induced angiogenic factors like vascular endothelial growth factor (VEGF). Cardiac expression of VEGF and its receptors are decreased in diabetic rats 3, 4 and in patients with diabetes, 3 whereas VEGF and its receptors, paradoxically, are increased in the diabetic retina, even in animal models where proliferative diabetic retinopathy does not occur. 3, 5 Both insulin resistance and hyperglycemia, present in most patients with diabetes, may affect angiogenic potential. Insulin action is necessary for appropriate expression of VEGF 6 (see Figure) , and rats with obesity-associated nondiabetic insulin resistance have decreased expression of VEGF and VEGF receptors 3 and decreased capillary density in the heart. 6 Hyperglycemia itself may inhibit angiogenesis, for example through formation of advanced glycation end-products (AGE). As an example modification of (basic) fibroblast growth factor-2 (FGF2) by AGE, 7 as shown by several independent groups, inhibits its angiogenic action. Even though many studies have shown that AGE increase proangiogenic functions of cultured endothelial cells, the compound effect of AGE in vivo may be an impairment of ischemia-induced angiogenesis because inhibition of AGE formation improves angiogenesis in diabetic mice. 1 In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Luo et al 8 examined another mechanism of impaired angiogenesis in diabetes, protein modification by O-linked ␤-N-acetylglucosamine (O-GlcNAc). Such O-linked glycosylation may affect nuclear and cytosolic proteins as a posttranslational modification on serine or threonine residues. This modification is dynamic, enzymatically regulated, and often modifies protein function. 9 It can be reciprocal to phosphorylation of the same residue because glycosylation prevents phosphorylation. 9 O-linked glycosylation of certain proteins is increased in diabetes because increased cellular uptake of glucose activates the hexosamine pathway, which metabolizes glucose as an alternative to other metabolic pathways like glycolysis. One product of the hexosamine pathway, uridine-diphospho-N-acetylglucosamine (UDPG1cNAc), is a substrate in the reaction that forms O-linked glycosylation. 10 Activation of the hexosamine pathway is not only a result of increased substrate availability during hyperglycemia. In patients with diabetes, the expression of glutamine:fructose-6-phosphate amidotransferase (GFAT), the rate-limiting enzyme for the hexosamine pathway, is increased in several tissues prone to complications. 11 Modulation of proteins by O-GlcNAc has been shown to modify DNA binding, enzyme activity, protein-protein interactions, the half-life of proteins, and subcellular localization.
To study the effect of diabetes, Luo et al 8 used aorta from animal models of human type 1 and type 2 diabetes, respectively, namely mice with streptozotocin-induced diabetes and mice fed a high-fat diet for 3 months. To study the effects of actvation of the hexosamine pathway more directly, they incubated mouse aorta with medium containing glucosamine, which is a substrate for the hexosamine pathway. There were increases of Ϸ50% in immunoreactive O-GlcNAc in aorta lysate and in sprouting of vascular cells from rings of aorta incubated in Matrigel.
The Figure) , this mechanism of Akt inactivation could affect angiogenic actions of many hormones, growth factors, and cytokines. As discussed by the authors it is readily appararent from the O-GlcNAc immunoblots of aorta lysate from diabetic animals ( Figure 1 13 which has proangiogenic effects. Therefore, confirmation of Luo et al's findings in vivo is critical, both because of the complexity of the true diabetic condition and because angiogenesis is determined by a range of factors beyond vascular cell proliferation and morphology, including production of growth factors and cytokines by interstitial cells and immune cells and modification of the extracellular matrix. It will also be important to determine quantitatively how much the mechanism of O-GlcNAc modification in diabetes contributes to inhibition in endothelial cells of the PI3K/Akt pathway, which can also be affected by other mechanisms, like activation of PKC 14 (see Figure) . Furthermore, the authors' results cannot explain the paradoxically increased angiogenesis in proliferative diabetic retinopathy despite the fact that O-GlcNAc protein modification is probably observed in all vascular tissues, including the retina.
Future studies will explore which proteins in vascular tissue are most susceptible to O-GlcNAc modification and describe in more detail how such glycosylation is regulated. Results from research in this area should provide new targets 
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with the purpose of improving angiogenesis in patients with diabetes, with the hope of preventing or treating heart failure, chronic ulcers, loss of limb, and shortened life span in patients with diabetes. It is likely that O-GlcNAc protein modification is only one piece of a puzzle that makes up the complex of vascular abnormalities in diabetes and insulin resistance. More work in this area is clearly needed because of the rapid increase in prevalence of insulin resistance and diabetes in many of the populations of the world.
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